Is GE Healthcare Technologies, Inc. overvalued or undervalued?

As of 7 November 2025, the valuation grade for GE Healthcare Technologies, Inc. moved from attractive to very attractive. Based on the current metrics, the company appears to be undervalued. The P/E ratio stands at 14, significantly lower than the peer average of approximately 15.07, while the EV to EBITDA ratio of 11.16 also suggests a favorable valuation compared to peers like Edwards Lifesciences Corp., which has an EV to EBITDA of 26.51. Additionally, the PEG ratio of 0.39 indicates strong growth potential relative to its price.
In comparison to its peers, GE Healthcare Technologies is positioned well with a ROE of 25.79% and a ROCE of 18.89%, reflecting efficient use of equity and capital. However, the company's recent stock performance has lagged behind the S&P 500, with a year-to-date return of -6.56% compared to the index's 14.40%. This underperformance may present a buying opportunity given the attractive valuation metrics.